Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 347

1.

Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus.

Aringer M, Steiner G, Graninger WB, Höfler E, Steiner CW, Smolen JS.

Arthritis Rheum. 2007 Jan;56(1):274-9.

2.

Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study.

Aringer M, Graninger WB, Steiner G, Smolen JS.

Arthritis Rheum. 2004 Oct;50(10):3161-9.

4.

Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients.

Aringer M, Houssiau F, Gordon C, Graninger WB, Voll RE, Rath E, Steiner G, Smolen JS.

Rheumatology (Oxford). 2009 Nov;48(11):1451-4. doi: 10.1093/rheumatology/kep270. Epub 2009 Sep 11.

5.
6.

Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy.

De Rycke L, Kruithof E, Van Damme N, Hoffman IE, Van den Bossche N, Van den Bosch F, Veys EM, De Keyser F.

Arthritis Rheum. 2003 Apr;48(4):1015-23.

7.

Efficacy and safety of infliximab in active SLE: a pilot study.

Uppal SS, Hayat SJ, Raghupathy R.

Lupus. 2009 Jul;18(8):690-7. doi: 10.1177/0961203309102557.

PMID:
19502264
8.

Accumulation of plasma nucleosomes upon treatment with anti-tumour necrosis factor-alpha antibodies.

D'Auria F, Rovere-Querini P, Giazzon M, Ajello P, Baldissera E, Manfredi AA, Sabbadini MG.

J Intern Med. 2004 Mar;255(3):409-18.

9.

Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha.

Eriksson C, Engstrand S, Sundqvist KG, Rantapää-Dahlqvist S.

Ann Rheum Dis. 2005 Mar;64(3):403-7. Epub 2004 Aug 5.

10.

Autoantibodies to the translational suppressors T cell intracytoplasmic antigen 1 and T cell intracytoplasmic antigen 1-related protein in patients with rheumatic diseases: increased prevalence in systemic lupus erythematosus and systemic sclerosis and correlation with clinical features.

Jimenez-Boj E, Kedersha N, Tohidast-Akrad M, Karlhofer FM, Stummvoll G, Zimmermann C, Ulrich W, Guiducci S, Hoefler E, Aringer M, Schett G, Matucci-Cerinic M, Smolen JS, Steiner G.

Arthritis Rheum. 2008 May;58(5):1226-36. doi: 10.1002/art.23435.

11.

Non-response to infliximab may be due to innate neutralizing anti-tumour necrosis factor-alpha antibodies.

Ebert EC, Das KM, Mehta V, Rezac C.

Clin Exp Immunol. 2008 Dec;154(3):325-31. doi: 10.1111/j.1365-2249.2008.03773.x. Epub 2008 Sep 23.

12.
13.

BioPlex 2200 multiplexed system: simultaneous detection of anti-dsDNA and anti-chromatin antibodies in patients with systemic lupus erythematosus.

Bardin N, Desplat-Jego S, Daniel L, Jourde Chiche N, Sanmarco M.

Autoimmunity. 2009 Jan;42(1):63-8. doi: 10.1080/08916930802354906.

PMID:
19127456
15.

Induction of autoantibodies in refractory rheumatoid arthritis treated by infliximab.

Allanore Y, Sellam J, Batteux F, Job Deslandre C, Weill B, Kahan A.

Clin Exp Rheumatol. 2004 Nov-Dec;22(6):756-8.

PMID:
15638051
16.

Efficacy and safety of TNF-blocker therapy in systemic lupus erythematosus.

Aringer M, Smolen JS.

Expert Opin Drug Saf. 2008 Jul;7(4):411-9. doi: 10.1517/14740338.7.4.411 . Review.

PMID:
18613805
17.

Anti-tumor necrosis factor therapy in patients with difficult-to-treat lupus nephritis: a prospective series of nine patients.

Matsumura R, Umemiya K, Sugiyama T, Sueishi M, Umibe T, Ichikawa K, Yoshimura M; Study Group on Nephrology at the National Hospital Organization of Japan.

Clin Exp Rheumatol. 2009 May-Jun;27(3):416-21.

PMID:
19604433
18.

Evolution of antinuclear antibodies and clinical patterns in patients with active rheumatoid arthritis with longterm infliximab therapy.

Comby E, Tanaff P, Mariotte D, Costentin-Pignol V, Marcelli C, Ballet JJ.

J Rheumatol. 2006 Jan;33(1):24-30.

PMID:
16395746
19.

The role of tumor necrosis factor-alpha in systemic lupus erythematosus.

Aringer M, Smolen JS.

Arthritis Res Ther. 2008;10(1):202. doi: 10.1186/ar2341. Epub 2008 Jan 23. Review.

Items per page

Supplemental Content

Write to the Help Desk